Your browser is no longer supported. Please, upgrade your browser.
Settings
CASC Cascadian Therapeutics, Inc. daily Stock Chart
CASC [NASD]
Cascadian Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.34 Insider Own0.40% Shs Outstand50.56M Perf Week0.10%
Market Cap505.60M Forward P/E- EPS next Y-1.07 Insider Trans0.00% Shs Float50.33M Perf Month115.98%
Income-51.70M PEG- EPS next Q-0.29 Inst Own83.40% Short Float1.29% Perf Quarter146.91%
Sales- P/S- EPS this Y-54.70% Inst Trans2.19% Short Ratio0.69 Perf Half Y178.55%
Book/sh2.47 P/B4.05 EPS next Y13.00% ROA-39.80% Target Price9.00 Perf Year157.73%
Cash/sh2.02 P/C4.96 EPS next 5Y- ROE-42.30% 52W Range3.18 - 10.21 Perf YTD170.27%
Dividend- P/FCF- EPS past 5Y14.10% ROI- 52W High-2.06% Beta3.86
Dividend %- Quick Ratio11.90 Sales past 5Y- Gross Margin- 52W Low214.47% ATR0.23
Employees57 Current Ratio11.90 Sales Q/Q- Oper. Margin- RSI (14)92.25 Volatility0.28% 2.10%
OptionableYes Debt/Eq0.00 EPS Q/Q46.50% Profit Margin- Rel Volume0.46 Prev Close10.00
ShortableYes LT Debt/Eq0.00 EarningsMar 08 AMC Payout- Avg Volume942.44K Price10.00
Recom2.60 SMA2010.27% SMA5067.70% SMA200123.78% Volume434,009 Change0.00%
Jan-31-18Downgrade Raymond James Outperform → Mkt Perform
Feb-16-18 08:00AM  Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period Business Wire
Feb-09-18 08:30AM  Todays Research Reports on Trending Tickers: Bellicum Pharmaceuticals and Cascadian Therapeutics ACCESSWIRE
Feb-08-18 06:26PM  SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Cascadian Therapeutics, Inc. Buyout Business Wire
06:10PM  ACT NOW: Monteverde & Associates PC Announces An Investigation of Cascadian Therapeutics, Inc. - CASC ACCESSWIRE
05:39PM  Seattle Genetics Commences Tender Offer for Cascadian Therapeutics, Inc. Business Wire
08:20AM  Todays Research Reports on Trending Tickers: Cascadian Therapeutics and UnitedHealth Group ACCESSWIRE
Feb-06-18 06:25PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Cascadian Therapeutics, Inc. - CASC ACCESSWIRE
11:21AM  RM LAW Announces Investigation of Cascadian Therapeutics, Inc. PR Newswire
Feb-03-18 10:32AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Feb-02-18 07:20AM  Wired News Seattle Genetics to Acquire Cascadian Therapeutics ACCESSWIRE
Feb-01-18 09:30AM  SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of Cascadian Therapeutics, Inc. - CASC PR Newswire
08:03AM  Cascadian Therapeutics Scores Big On Seattle Genetics Acquisition Market Exclusive
Jan-31-18 04:52PM  CASCADIAN THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout Business Wire +70.51%
03:22PM  Here's Why Cascadian Therapeutics Jumped Up to 73.1% Today Motley Fool
01:53PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Cascadian Therapeutics, Inc. to Seattle Genetics, Inc. for $10.00 Per Share is Fair to Shareholders Business Wire
11:34AM  Why Cascadian Therapeutics Inc (USA) Is Todays Best Biotech Stock SmarterAnalyst
11:00AM  Why Cascadian Therapeutics Shares Are Skyrocketing 24/7 Wall St.
08:26AM  Cascadian (CASC) Alert: Johnson Fistel Investigates Proposed Sale of Cascadian Therapeutics, Inc.; Is $10.00 a Fair Price for Shareholders? PR Newswire
06:30AM  Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline Business Wire
Jan-18-18 08:05AM  Investor Expectations to Drive Momentum within Malibu Boats, Lincoln Electric, Cascadian Therapeutics, LRAD, Lancaster Colony, and Nelnet Discovering Underlying Factors of Influence GlobeNewswire
Jan-04-18 08:30AM  Cascadian Therapeutics Announces 2018 Outlook and Recent Progress GlobeNewswire
Jan-02-18 08:30AM  Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency GlobeNewswire
Dec-13-17 08:35AM  Cascadian Therapeutics Added to the Nasdaq Biotechnology Index GlobeNewswire +5.19%
Dec-07-17 04:05PM  Prolonged Progression-Free Survival Reinforces Tucatinibs Potential for Patients with Advanced HER2+ Metastatic Breast Cancer GlobeNewswire
Nov-28-17 08:05AM  Cascadian, Potential Catalysts, Recent Highlights, Tucatinib Update ACCESSWIRE
Nov-12-17 04:31AM  Edited Transcript of CASC earnings conference call or presentation 8-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-08-17 05:01PM  Cascadian Therapeutics reports 3Q loss Associated Press
04:01PM  Cascadian Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
12:40PM  Cascadian Therapeutics Inc. to Host Earnings Call ACCESSWIRE
Nov-01-17 09:19AM  Cascadian Therapeutics to Report Third Quarter 2017 Financial Results on November 8, 2017 GlobeNewswire -5.01%
Oct-24-17 08:05AM  Cascadian Therapeutics to Participate in Panel Discussions at Two Conferences in November GlobeNewswire
Sep-27-17 07:00AM  Cascadian Therapeutics Announces FDA Orphan Drug Designation Granted to Tucatinib for the Treatment of HER2+ Metastatic Colorectal Cancer GlobeNewswire
Sep-20-17 09:00AM  Cascadian Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-12-17 05:51PM  Edited Transcript of CASC earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Sep-11-17 06:00AM  Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress GlobeNewswire
Sep-07-17 01:59PM  2 Names Barclays Is Now Bearish On In Biotech Benzinga
Aug-28-17 08:30AM  Cascadian Therapeutics Announces Poster Presentations on Tucatinib in Multiple Tumor Types at the European Society for Medical Oncology (ESMO) 2017 Congress GlobeNewswire
Aug-10-17 01:07AM  Cascadian Therapeutics reports 2Q loss Associated Press
Aug-08-17 04:01PM  Cascadian Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
11:00AM  Investor Network: Cascadian Therapeutics Inc. to Host Earnings Call ACCESSWIRE
Aug-01-17 08:30AM  Cascadian Therapeutics to Report Second Quarter 2017 Financial Results on August 8, 2017 GlobeNewswire
Jul-11-17 08:00AM  Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in Europe GlobeNewswire
Jun-08-17 08:00AM  Cascadian Therapeutics Lead Candidate, Tucatinib, Receives Orphan Drug Designation from FDA for Treatment of Breast Cancer Patients with Brain Metastases GlobeNewswire
May-31-17 08:30AM  Cascadian Therapeutics to Present at Jefferies 2017 Healthcare Conference GlobeNewswire
May-12-17 07:16PM  Edited Transcript of CASC earnings conference call or presentation 9-May-17 12:30pm GMT Thomson Reuters StreetEvents +6.91%
May-09-17 07:55PM  Edited Transcript of CASC earnings conference call or presentation 9-May-17 12:30pm GMT Thomson Reuters StreetEvents
10:19AM  Cascadian Therapeutics reports 1Q loss Associated Press
07:45AM  Investor Network: Cascadian Therapeutics Inc. to Host Earnings Call Accesswire
07:00AM  Cascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for Today at 8:30 a.m. ET GlobeNewswire
May-01-17 08:56AM  Cascadian Therapeutics to Report First Quarter 2017 Financial Results on May 9, 2017 GlobeNewswire
Apr-05-17 08:00AM  Cascadian Therapeutics Highlights Preclinical Program Presentations at the American Association for Cancer Research Annual Meeting 2017 GlobeNewswire
08:00AM  Cascadian Therapeutics Highlights Preclinical Program Presentations at the American Association for Cancer Research Annual Meeting 2017
Mar-15-17 01:04PM  CASCADIAN THERAPEUTICS, INC. Financials
Mar-13-17 04:10PM  CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
04:01PM  Cascadian Therapeutics Announces Changes to Board of Directors GlobeNewswire
Mar-09-17 05:48PM  Cascadian Therapeutics reports 4Q loss Associated Press
05:48PM  Cascadian Therapeutics reports 4Q loss
04:49PM  CASCADIAN THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
04:01PM  Cascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Feb-27-17 09:00AM  Cascadian Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference GlobeNewswire +5.93%
Feb-03-17 05:02PM  CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement
Jan-27-17 04:08PM  CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
Jan-24-17 05:06PM  CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Materia
04:01PM  Gilead Sciences, DryShips Stuck in Tuesdays 52-Week Low Club
08:50AM  Cascadian Therapeutics Prices $82.5 Million Concurrent Offerings of Common Stock and Preferred Stock GlobeNewswire
Jan-23-17 04:03PM  CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
04:01PM  Cascadian Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock GlobeNewswire
Jan-05-17 08:00AM  Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress GlobeNewswire
Jan-04-17 08:00AM  Cascadian Therapeutics Appoints Dr. Marc L. Lesnick as Senior Vice President, Regulatory Affairs and Quality GlobeNewswire +8.97%
Dec-20-16 04:05PM  Should You Buy Alico, Inc. (ALCO)? Insider Monkey
04:05PM  Should You Buy Alico, Inc. (ALCO)? at Insider Monkey
Dec-12-16 05:45PM  Heres What Smart Money Think about Jones Energy Inc (JONE) Insider Monkey +7.61%
05:45PM  Heres What Smart Money Think about Jones Energy Inc (JONE) at Insider Monkey
Dec-10-16 10:16AM  Do Hedge Funds Love Invuity, Inc. (IVTY)? Insider Monkey
10:16AM  Do Hedge Funds Love Invuity, Inc. (IVTY)? at Insider Monkey
Dec-08-16 03:47PM  Biotech Movers And Shakers: Cascadian Therapeutics Inc (USA) (CASC) And Anthera Pharmaceuticals Inc (ANTH) Insider Monkey
03:47PM  Biotech Movers And Shakers: Cascadian Therapeutics Inc (USA) (CASC) And Anthera Pharmaceuticals Inc (ANTH) at Insider Monkey
Dec-07-16 07:26AM  CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards
07:00AM  Cascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive Breast Cancer to Support Registration GlobeNewswire
Dec-01-16 08:38AM  Cascadian Therapeutics, Inc. :CASC-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016 -11.41%
Nov-29-16 07:03AM  Splits Calendar: Cascadian Therapeutics splits before market open today (1:6 ratio)
Nov-28-16 08:00AM  Cascadian Therapeutics Strengthens Management Team with Key Hires, Monique M. Greer and Marc C. Chamberlain, M.D. GlobeNewswire
Nov-23-16 04:11PM  CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Sub
04:05PM  Cascadian Therapeutics Announces Stockholders and Board of Directors Approve Reverse Stock Split GlobeNewswire
Nov-15-16 08:00AM  Cascadian Therapeutics Announces Presentations of Updated Clinical Data at the 2016 San Antonio Breast Cancer Symposium GlobeNewswire
Nov-07-16 05:23PM  CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
05:08PM  Cascadian Therapeutics reports 3Q loss
04:05PM  Cascadian Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
Oct-10-16 07:10AM  Cascadian Therapeutics Announces Presentation of Tucatinib in Combination Therapy in Patients with Cutaneous HER2+ Metastatic Breast Cancer GlobeNewswire
Oct-06-16 11:18AM  Cascadian Therapeutics (CASC) Shares March Higher, Can It Continue?
Oct-04-16 04:19PM  CASCADIAN THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:12PM  Cascadian Therapeutics Announces Proposal for Reverse Stock Split GlobeNewswire
Sep-28-16 08:00AM  Cascadian Therapeutics Announces Poster Presentations on Tucatinib at the European Society of Medical Oncology (ESMO) 2016 Congress GlobeNewswire
Sep-20-16 08:00AM  Cascadian Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference GlobeNewswire +8.73%
Sep-16-16 12:40PM  Cascadian Therapeutics, Inc. :CASC-US: Earnings Analysis: Q2, 2016 By the Numbers : September 16, 2016
Sep-06-16 08:52AM  How Cascadian Therapeutics (CASC) Stock Stands Out in a Strong Industry
08:00AM  Cascadian Therapeutics to Present at the Rodman & Renshaw 18th Annual Global Investment Conference GlobeNewswire
Aug-31-16 04:02PM  Cascadian Therapeutics Announces Approval of Nonproprietary Name tucatinib for Lead Product Candidate ONT-380 GlobeNewswire
Aug-25-16 08:15PM  Breaking Down Baupost's Holdings for Q2 (LMCA, QVCA) at Investopedia
Cascadian Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress. In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology. The company was formerly known as Oncothyreon Inc. and changed its name to Cascadian Therapeutics, Inc. in June 2016. Cascadian Therapeutics, Inc. was founded in 1985 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PETERSON SCOTT ROBERTChief Scientific OfficerJan 11Option Exercise0.002,82504,562Jan 16 05:28 PM
Walker Luke NathanielSVP, Clinical DevelopmentJan 11Option Exercise0.001,95005,940Jan 16 05:29 PM
Myers Scott DunsethPresident and CEOJan 11Option Exercise0.0010,500060,216Jan 16 05:26 PM
EASTLAND JULIA MARIECFO & CBOJan 11Option Exercise0.002,82506,160Jan 16 05:25 PM
Christianson GaryChief Operating OfficerJan 11Option Exercise0.002,82507,438Jan 16 05:24 PM
LOVE TED WDirectorSep 24Option Exercise0.002,375037,988Sep 26 05:21 PM
SPIEGELMAN DANIEL KDirectorSep 24Option Exercise0.002,375021,600Sep 26 05:22 PM
James Steven PDirectorSep 24Option Exercise0.002,375014,271Sep 26 05:20 PM
HENNEY CHRISTOPHER SDirectorSep 24Option Exercise0.002,375060,779Sep 26 05:19 PM